Table 2:
3-year univariate outcomes for clinical trial patients by conditioning intensity
| MAC (N = 40) | RIC (N = 40) | |||
|---|---|---|---|---|
| Outcomes | N | Prob (90% CI) | N | Prob (90% CI) |
|
| ||||
| Overall survival | 40 | 40 | ||
| 1-year | 29 | 72.5 (60.3–83.2)% | 29 | 79.9 (68.6–89.2)% |
| 3-year | 11 | 62.4 (49.5–74.5)% | 11 | 69.6 (55.8–81.8)% |
| Non-relapse mortality | 40 | 40 | ||
| 1-year | 24 | 7.5 (2.1–15.8)% | 26 | 10 (3.6–19.2)% |
| 3-year | 9 | 10 (3.5–19.2)% | 9 | 14.7 (5.7–26.9)% |
| Relapse | 40 | 40 | ||
| 1-year | 24 | 35 (23-48)% | 26 | 20 (10.6–31.5)% |
| 3-year | 9 | 50.5 (36.3–64.7)% | 9 | 29.4 (17.7–42.7)% |
| Progression-free survival | 40 | 40 | ||
| 1-year | 23 | 57.5 (44.5–70)% | 25 | 70 (57.5–81.1)% |
| 3-year | 8 | 39. 5 (26.4–53.4)% | 8 | 55.9 (41.6–69.8)% |
| Chronic GVHD | 40 | 40 | ||
| 1-year | 15 | 37.5 (25.2–50.6)% | 24 | 20 (10.6–31.5)% |
| 3-year | 6 | 37.5 (25.2–50.6)% | 6 | 20 (10.6–31.5)% |
| Severe Chronic GVHD | 40 | 40 | ||
| 1-year | 25 | 12.5 (5.2–22.4)% | 29 | 5 (0.9–12.2)% |
| 3-year | 8 | 12.5 (5.2–22.4)% | 12 | 5 (0.9–12.2)% |
| GVHD-/relapse-free survival (GRFs) | 40 | 40 | ||
| 1-year | 10 | 25 (14.7–37)% | 19 | 55 (42–67.6)% |
| 3-year | 3 | 16.9 (8.2–27.8)% | 5 | 44.3 (30.6–58.5)% |